96 completed, 16 unknown, 8 terminated, 3 not yet recruiting. 42 Phase 3, 39 Phase 4, 20 Phase 1, 9 Phase 2, 7 Not applicable.
Follow saxagliptin: new trials by email Literature Review of saxagliptin trials Research Report on saxagliptin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Restoring Awareness Saxagliptin (Mylan Pharmaceuticals Inc., NDC: 0378-4706-93) - Vegetative State, Minimally Conscious State | Phase 2 | Not yet recruiting | Casa Colina Hospital and Centers for Healthcare | 24 | 2026-11-15 | 2026-11-05 |
| Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes - Type 2 Diabetes | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 600 | 2026-06-15 | 2026-08-27 |
| Pattern of Treatment and Outcomes of Locally Advanced Rectal Carcinoma No Intervention (subjects were previously treated with Onglyza®) - Rectal Carcinoma | Not yet recruiting | Sohag University | 100 | 2026-03-01 | 2026-01-23 | |
| Robson Ten-Group Classification Study of Cesarean Section Rates in Assiut Hospitals No Intervention (subjects were previously treated with Onglyza®) - Cesarean Section, Maternal Health | Not yet recruiting | Assiut University | 770 | 2025-12-01 | 2025-09-26 | |
| Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, Pioglitazone 30mg - Type2diabetes | Phase 3 | Completed | University of Basrah | 243 | 2023-11-01 | 2025-03-30 |
| Cognitive Protective Effect of Newer Antidiabetic Drugs Dapagliflozin, Empagliflozin, Canagliflozin - Type 2 Diabetes | Unknown | Alexandria University | 100 | 2022-03-02 | 2022-07-26 | |
| To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus Patients dapagliflozin and saxagliptin - Type 2 Diabetes Mellitus | Phase 4 | Completed | AstraZeneca | 196 | 2021-04-07 | 2024-11-12 |
| SGLT-2 and DPP-4 Inhibition, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections. Empagliflozin / Linagliptin or Dapagliflozin/Saxagliptin Pill, Empagliflozin or Dapagliflozin Pill - Type 2 Diabetes, Urinary Tract Infections | Completed | University of Pisa | 60 | 2020-10-07 | 2025-07-18 | |
| Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP) Canagliflozin, DPP4 inhibitor, Liraglutide - Type 2 Diabetes Mellitus | Completed | AstraZeneca | 239990 | 2020-05-15 | 2024-08-30 | |
| Evaluation of Drug Interactions of Saxagliptin With Sildenafil in Healthy Volunteers Saxagliptin 5mg, Sildenafil 50 mg - Diabetes Mellitus, Type 2, Erectile Dysfunction With Diabetes Mellitus | Not applicable | Unknown | Ain Shams University | 18 | 2019-12-01 | 2019-11-20 |
| Tubular Markers in Response to Saxagliptin Therapy Saxagliptin 5mg - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Beni-Suef University | 80 | 2019-03-01 | 2020-08-20 |
| Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin Dapagliflozin 10 mg, Dapagliflozin 5 mg, Dapagliflozin 10 mg placebo to match - Type 2 Diabetes Mellitus | Phase 3 | Terminated | AstraZeneca | 41 | 2019-02-27 | 2022-05-31 |
| Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet - Diabetes Mellitus, Type 2, Cardiovascular Diseases | Phase 4 | Terminated | Sabyasachi Sen | 15 | 2018-10-22 | 2023-06-05 |
| Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy Triple combination therapy group, Premixed insulin therapy group - Type 2 Diabetes Mellitus | Phase 4 | Completed | Zhujiang Hospital | 130 | 2018-10-01 | 2024-03-18 |
| Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2. Dapagliflozin 10mg, Saxagliptin 5mg, Saxagliptin 5mg + Dapagliflozin 10 mg - Type2 Diabetes Mellitus | Phase 2 | Completed | University of Pisa | 48 | 2018-07-24 | 2022-11-08 |
| Neuropeptide Y and Sympathovagal Balance Saxagliptin 5mg, Placebo oral capsule, ergometric test in healthy volunteers - Physical Activity, Sympathetic Nervous System | Early Phase 1 | Completed | Eric Grouzmann | 7 | 2018-06-05 | 2019-05-01 |
| Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment Dapagliflozin 10 mg + Saxagliptin 5 mg, Placebo 1 10 mg + Placebo 2 5 mg - Type 2 Diabetes | Phase 4 | Terminated | University Hospital Tuebingen | 4 | 2018-02-02 | 2020-02-11 |
| Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old Dapagliflozin, Saxagliptin, Placebo - Diabetes Mellitus, Type 2 | Phase 3 | Completed | AstraZeneca | 256 | 2017-10-11 | 2024-06-21 |
| Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims Saxagliptin, Sulfonylurea - Diabetes | Completed | Brigham and Women's Hospital | 182126 | 2017-09-22 | 2023-08-01 | |
| A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration. 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR - Type 2 Diabetes Mellitus | Phase 1 | Completed | AstraZeneca | 85 | 2017-05-29 | 2017-08-14 |
Showing 20 of 127. Sign in to see all of them.
Diabetes Mellitus, Type 2 (97) · Diabetes Mellitus (14) · Diabetes Mellitus, Type 1 (4) · Glucose Intolerance (4) · Obesity (4) · Heart Failure (3) · Cardiovascular Diseases (2) · Cystic Fibrosis (2) · Insulin Resistance (2) · Prediabetic State (2) · Acute Coronary Syndrome (1) · Albuminuria (1) · Autoimmune Diseases (1) · Coronary Artery Disease (1) · Diabetic Foot (1)
AstraZeneca (64) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · Shanghai Jiao Tong University School of Medicine (3) · Brigham and Women's Hospital (2) · Ram Weiss (2) · The University of Texas Health Science Center at San Antonio (2) · University of Pisa (2) · Ain Shams University (1) · Alexandria University (1) · Assistance Publique - Hôpitaux de Paris (1) · Assiut University (1) · Astellas Pharma Inc (1) · Baylor College of Medicine (1) · Beijing Chao Yang Hospital (1) · Beni-Suef University (1)
United States (54) · Mexico (22) · China (21) · Canada (17) · Germany (14) · Hungary (13) · India (13) · Russia (13) · Poland (12) · United Kingdom (12) · Puerto Rico (11) · South Korea (11) · Argentina (9) · Italy (9) · South Africa (9)
Deborah Price, MSc (7) · Pierre Ernst, MD, MSc (3) · Eitan Kerem, MD (2) · Guang Ning, MD. PHD (2) · Linong Ji, Professor (2) · Peter Ohman, MD (2) · Peter Ohman, MD, PhD (2) · Ralph A DeFronzo, MD (2) · Absalaon D Gutierrez, MD (1) · Ahmed A Elberry, prof (1) · Ahmed F El-Yazbi, PhD (1) · Ambika Babu, MD,MS (1) · Amr El-Feky, MD (1)
PMID 27402391, PMID 27033025, PMID 23795975, PMID 21680990, PMID 25414932, PMID 19114612, PMID 21819160, PMID 21871686, PMID 23549864, PMID 23802840, PMID 25352655, PMID 29802530, PMID 31364269, PMID 38770818, PMID 1244564, PMID 1563586, PMID 16033281, PMID 16612330, PMID 17098089, PMID 17337495, PMID 17387446, PMID 17622601, PMID 18539916, PMID 18539917, PMID 18784090, PMID 19336687, PMID 20092585, PMID 20388897, PMID 21206136, PMID 21332627, PMID 21342412, PMID 21562064, PMID 21562067, PMID 22025647, PMID 22081481, PMID 22093196, PMID 22192246, PMID 22313154, PMID 22446170, PMID 22517736, PMID 22668067, PMID 22804249, PMID 22828124, PMID 23020253, PMID 23384119, PMID 23439165, PMID 23524641, PMID 23563279, PMID 23564755, PMID 23638466
2015 (3), 1UH3TR001372-01 (1), 2014 (1), 2018 (1), R01DK024092 (1)